Here we report a patient with clearly demarcated, pathologically heterogenous HER2 + /TNBC breast cancer treated with a hybrid neoadjuvant regimen combining parts of a modified KN522 regimen with paclitaxel-carboplatin-trastuzumab-pertuzumab (TCHP), ultimately achieving a pathologic complete response at the time of surgery. Here, ERBB2 is linked to breast carcinoma.